Moderna’s genetic COVID-19 vaccine data shows disturbing results for children after inoculation.
Randomized, placebo-controlled trials (RCT’s) are considered to be the gold standard of drug tests. Trial subjects are randomly placed in either a study group to get the drug or in a control group which gets a placebo injection. This randomness prevents creating a selective group. Furthermore, neither the clinician nor the subject knows which group they are in, which will prevent biased testing. This is to say that both the clinician and subject are blinded so the trial is considered ‘double blinded.’ All pharmaceutical companies are required to run strictly monitored trials to apply for their drugs’ approvals.
Moderna submitted the results of such a RCT for people under the age of 18 for its mRNA vaccine approval. They were measuring anti-nucleocapsid antibodies (anti-N Ab). Nucleocapsid proteins are located inside the virus, to which the body can produce antibodies against, which acts as an indicator of natural immunity in future. This is termed seroconversion as the body, when infected, converts from seronegative (no N antibodies) to seropositive (N antibodies present). Unfortunately, many people that have been infected with SARS-CoV-2 do not generate nucleocapsid-directed antibodies.
The importance of this cannot be overstated. The mRNA vaccines focus only on the highly variable spike proteins on the surface of the virus and none of the other 27 proteins found within the virus. Natural immunity elicits the production of antibodies against the spike, nucleocapsid and most of the other viral proteins. Those antibodies that target the spike, membrane and envelope proteins of SARS-CoV-2 are the most protective, because they are all found on the outside of the SARS-CoV-2 virus particles and easily accessible.
Here is a link to Moderna’s trial study
In total, there were 1,789 participants under the age of 18. After unblinding the trial, it was revealed that there were 1,298 in the placebo group, 648 of which tested positive for SARS CoV-2 as per a positive PCR test during the 150 day trial period. There were 491 in the vaccinated group, of which 52 tested positive during the trial. Note that the natural immunity status in both groups was only accessed on the basis of nucleocapsid antibody detection, which is variable amongst SARS-CoV-2 infected people. Nevertheless, if we stopped here, the mRNA vaccine would look relatively good at minimizing COVID infections. Does this short term gain come with long term pain? Let’s take a look.
What is the risk of a SARS-CoV-2 infection in an under 20 years old so we can compare the benefit? According to Canada’s Chief Science Advisor in an earlier report, 1.5% of young people under 20 needed to be hospitalized (they make up 22% of the population) and none died in Canada. In short, young people have virtually negligeable risk of a severe COVID-19. Question, do we really need to vaccinate the young to reduce the rate of infection if there is little risk or benefit such as protection from more severe symptoms or death as in older adults? Here is the link-
Now the bad news! Moderna’s trial showed (Table 1 in the first link) that, of the 648 infections in the placebo group, 93.4% showed a seroconversion from negative to positive. This is to say that 93.4% of the non-vaccinated now show evidence of long term natural immunity. In the vaccinated group of 52 that still got COVID-19, however, only 40.4% showed the seroconversion after 150 days. This is hugely significant. It shows that Moderna’s mRNA vaccination, as shown in their own gold standard trial, is hindering the body from establishing long term natural immunity. Time will reveal more about the long term consequences that may be created by rushing to vaccinate the younger generation at the expense of compromising their immune system.